Suzhou, China; January 5, 2018 -- CStone Pharmaceuticals , a biopharmaceutical company devoted to developing new generation of innovative drugs, announced today that Dr. Frank Jiang, CEO of CStone Pharmaceuticals, will be giving an invited presentation at the 36th Annual J.P. Morgan Healthcare Conference that will be held in San Francisco, CA from January 8-11, 2018. The CStone presentation is scheduled for Wednesday, January 10 at 13:00 PM Pacific Standard Time.

Dr. Jiang will give an overview of CStone's corporate strategy, the latest product pipeline, as well as recent progresses in clinical development of CS1001 (a fully human anti-PD-L1 antibody currently in Phase I study) and strategic partnerships.

For general information, please contact: [email protected]

About CStone Pharmaceuticals

CStone Pharmaceuticals is a biopharmaceutical company devoted to the development of a new generation of innovative drugs. With its broad immuno-oncology pipeline, CStone is pursuing a development strategy focusing on combination therapy.

In July of 2016, CStone Pharmaceuticals announced the completion of its $150 million Series A financing, led by three prestigious VC/PE funds: Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures. All members of the management team are seasoned executives from top multinational pharmaceutical companies.

CStone has successfully built up an industry leading team with clinical development and translational medicine as its core competence. This enables CStone to accelerate drug approval timeline, while at the same time, apply global standard practices to ensure clinical trial quality.

The unique advantages in clinical development, funding and pipeline also positions CStone as the partner of choice for multinational pharmaceutical / biotech companies to develop drugs in China and the Asia Pacific region.